Ovarian Cancers: Evolving Paradigms in Research and Care (2016)
Chapter: Appendix A: Acronyms and Abbreviations
Visit
NAP.edu/10766
to get more information about this book, to buy it in print, or to
download it as a free PDF.
Previous Chapter:
7 Dissemination and Implementation
Next Chapter: Appendix B: Glossary
Suggested Citation:
"Appendix A: Acronyms and Abbreviations." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press.
doi: 10.17226/21841.
| ABOG | American Board of Obstetrics and Gynecology |
| ABOUT | American BRCA Outcomes and Utilization of Testing [Patient-Powered Research Network] |
| ACA | Patient Protection and Affordable Care Act |
| ACMG | American College of Medical Genetics and Genomics |
| ACOG | American Congress of Obstetricians and Gynecologists |
| ACS | American College of Surgeons |
| ACT | adoptive cell therapy |
| AHRQ | Agency for Healthcare Research and Quality |
| ASCO | American Society of Clinical Oncology |
| BER | base excision repair |
| BMI | body mass index |
| BOT | borderline ovarian tumor |
| BRCA | breast cancer genes 1 and 2 |
| BSO | bilateral salpingo-oophorectomy |
| BSOR | bilateral salpingectomy with ovarian retention |
| CA-125 | cancer antigen 125 |
| CAM | complementary and alternative medicine |
| CCC | clear cell carcinoma |
| CDC | Centers for Disease Control and Prevention |
| CMS | Centers for Medicare & Medicaid Services |
| CPTAC | Clinical Proteomic Tumor Analysis Consortium |
| CT | computed tomography |
Suggested Citation:
"Appendix A: Acronyms and Abbreviations." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press.
doi: 10.17226/21841.
| CTCAE | Common Terminology Criteria for Adverse Events |
| CTEP | Cancer Therapy Evaluation Program |
| D&I | dissemination and implementation |
| DNA | deoxyribonucleic acid |
| DoD | U.S. Department of Defense |
| EBI | evidence-based intervention |
| EC | endometrioid carcinoma |
| EGFR | epidermal growth factor receptor |
| EMT | epithelial to mesenchymal transition |
| FDA | U.S. Food and Drug Administration |
| FIGO | International Federation of Gynecology and Obstetrics |
| FORCE | Facing Our Risk of Cancer Empowered |
| FTE | fallopian tube epithelium |
| GEMM | genetically engineered mouse model |
| GH | growth hormone |
| GOG | Gynecologic Oncology Group |
| HBOC | hereditary breast and ovarian cancer [syndrome] |
| HE-4 | human epididymis protein 4 |
| HGSC | high-grade serous carcinoma |
| HHS | U.S. Department of Health and Human Services |
| HPV | human papillomavirus |
| HR | homologous recombination |
| IGF-1 | insulin-like growth factor 1 |
| IOM | Institute of Medicine |
| IP | intraperitoneal |
| IrRC | immune-related response criteria |
| IV | intravenous |
| LBA | laboratory biomarker analysis |
| LGSC | low-grade serous carcinoma |
| MAPK | mitogen-activated protein kinase |
| MC | mucinous carcinoma |
| miR | microRNA |
| MMS | multimodal screening |
| MRI | magnetic resonance imaging |
Suggested Citation:
"Appendix A: Acronyms and Abbreviations." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press.
doi: 10.17226/21841.
| NACT | neoadjuvant chemotherapy |
| NCCN | National Comprehensive Cancer Network |
| NCI | National Cancer Institute |
| NGS | next-generation sequencing |
| NHEJ | nonhomologous end joining |
| NIH | National Institutes of Health |
| NOCC | National Ovarian Cancer Coalition |
| NRC | National Research Council |
| NSGC | National Society of Genetic Counselors |
| OC | oral contraceptive |
| OCNA | Ovarian Cancer National Alliance |
| OCRF | Ovarian Cancer Research Fund |
| OCRP | Ovarian Cancer Research Program |
| OCS | Office of Cancer Survivorship |
| OSE | ovarian surface epithelium |
| PARP | poly ADP ribose polymerase |
| PCORI | Patient-Centered Outcomes Research Institute |
| PCOS | polycystic ovarian syndrome |
| PDS | primary debulking surgery |
| PDX | patient-derived xenograft |
| PFS | progression-free survival |
| PID | pelvic inflammatory disease |
| PLCO | prostate, lung, colorectal, and ovarian [cancer screening trial] |
| PPC | primary palliative care |
| PRO | patient-reported outcome |
| QOL | quality of life |
| RCT | randomized controlled trial |
| RMI | Risk of Malignancy Index |
| RNA | ribonucleic acid |
| ROCA | risk of ovarian cancer algorithm |
| ROMA | risk of ovarian malignancy algorithm |
| RRSO | risk-reducing salpingo-oophorectomy |
| SBT | serous borderline tumor |
| SEER | surveillance, epidemiology, and end results |
| SGO | Society of Gynecologic Oncology |
| SNP | single-nucleotide polymorphism |
| SPC | specialty palliative care |
Suggested Citation:
"Appendix A: Acronyms and Abbreviations." National Academies of Sciences, Engineering, and Medicine. 2016. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press.
doi: 10.17226/21841.
| SPORE | Specialized Program of Research Excellence |
| STIC | serous tubal intraepithelial carcinoma |
| TCGA | The Cancer Genome Atlas |
| TVU | transvaginal ultrasound |
| UKCTOCS | United Kingdom Collaborative Trial of Ovarian Cancer Screening |
| USPSTF | U.S. Preventive Services Task Force |
| VEGF | vascular endothelial growth factor |
| VEGFR | vascular endothelial growth factor receptor |
| WOO | window of opportunity |
Subscribe to Emails from the National Academies
Stay up to date on activities, publications, and events by subscribing to email updates.